VA's McKesson Pharmaceutical Prime Vendor contract saw $658M in FY2021 spending, with a $21.9M delivery order

Contract Overview

Contract Amount: $658,334,795 ($658.3M)

Contractor: Mckesson Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2021-03-01

End Date: 2021-03-31

Contract Duration: 30 days

Daily Burn Rate: $21.9M/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2021 MARCH

Place of Performance

Location: IRVING, DALLAS County, TEXAS, 75039

State: Texas Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $658.3 million to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2021 MARCH Key points: 1. The contract represents a significant portion of the VA's pharmaceutical spending, highlighting the importance of reliable supply chains. 2. Full and open competition was utilized, suggesting a robust market for pharmaceutical prime vendor services. 3. The contract's performance context is critical given the essential nature of pharmaceutical supplies for veteran healthcare. 4. McKesson Corporation's role as prime vendor indicates a concentrated market for these large-scale distribution services. 5. The firm-fixed-price contract type aims to provide cost certainty for the government. 6. The relatively short duration of the delivery order (30 days) suggests a need for agile and responsive fulfillment.

Value Assessment

Rating: good

The VA's Pharmaceutical Prime Vendor (PPV) program is a cornerstone of its healthcare system, ensuring timely access to medications. While specific per-unit cost data for this single delivery order is not provided, the overall contract value of $658 million in FY2021 suggests significant scale. Benchmarking against similar large-scale pharmaceutical distribution contracts would be necessary for a precise value-for-money assessment. However, the use of full and open competition generally supports competitive pricing.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, indicating that multiple qualified vendors were eligible to bid. The specific number of bidders is not detailed in the provided data, but the designation implies a competitive process designed to solicit the best offers. This approach is generally favored to ensure fair pricing and access to a broad range of capabilities.

Taxpayer Impact: Full and open competition typically benefits taxpayers by fostering a competitive environment that can drive down prices and encourage innovation, leading to better value for government spending.

Public Impact

Veterans across the nation benefit from consistent and timely access to essential pharmaceuticals. The contract ensures the availability of a wide range of pharmaceutical products necessary for medical treatment. The services delivered support the VA's mission to provide comprehensive healthcare to its beneficiaries. Geographic impact is nationwide, as the VA operates healthcare facilities across the United States. The contract supports a critical segment of the healthcare supply chain, indirectly impacting healthcare professionals within the VA system.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for price fluctuations in pharmaceutical markets could impact long-term cost-effectiveness.
Dependence on a single prime vendor for a large volume of pharmaceuticals could pose supply chain risks.
Ensuring compliance with stringent pharmaceutical handling and storage regulations requires continuous oversight.

Positive Signals

The use of full and open competition suggests a healthy market and potential for competitive pricing.
The firm-fixed-price contract type provides cost predictability for the government.
The scale of the contract indicates the contractor's capacity to meet significant demand.

Sector Analysis

The pharmaceutical distribution sector is characterized by large, established players managing complex supply chains. This contract falls within the broader healthcare and logistics industries, where efficiency, reliability, and regulatory compliance are paramount. The VA's spending on pharmaceutical prime vendors is a significant component of its healthcare budget, reflecting the high cost and essential nature of medications. Comparable spending benchmarks would involve analyzing other large federal agencies or healthcare systems that procure pharmaceuticals through prime vendors.

Small Business Impact

The provided data does not indicate any specific small business set-aside provisions for this contract. As a large prime vendor contract, the primary focus is on the prime contractor's capabilities. However, McKesson Corporation, like other large distributors, likely engages small businesses for subcontracting opportunities within its broader supply chain operations, though this is not explicitly detailed here.

Oversight & Accountability

Oversight for this contract would typically involve the Department of Veterans Affairs' contracting officers and program managers. Accountability measures are embedded in the contract terms, including performance standards and delivery schedules. Transparency is generally maintained through contract award databases and reporting requirements. Inspector General jurisdiction would apply in cases of fraud, waste, or abuse related to the contract.

Related Government Programs

Department of Defense Pharmaceutical Prime Vendor Program
Federal Supply Schedule (FSS) for Pharmaceuticals
National Acquisition Center (NAC) Contracts
VA Medical Care Programs

Risk Flags

Supply Chain Vulnerability
Potential for Price Escalation
Regulatory Compliance Risk
Dependence on Single Source

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $658.3 million to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2021 MARCH

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $658.3 million.

What is the period of performance?

Start: 2021-03-01. End: 2021-03-31.

What is McKesson Corporation's track record with the Department of Veterans Affairs for pharmaceutical prime vendor services?

McKesson Corporation has a long-standing relationship with the Department of Veterans Affairs (VA) as a pharmaceutical prime vendor. They have consistently been awarded significant contracts to supply medications to VA medical centers and facilities nationwide. Their track record generally reflects a capacity to manage large-scale distribution and meet the VA's demanding requirements for pharmaceutical availability and delivery. However, like any large contractor, there may have been instances of performance issues or contract disputes over the years, which would be detailed in contract performance reports and agency oversight records. The consistent awarding of these large contracts suggests a generally satisfactory performance history, but a deeper dive into specific performance metrics and any corrective actions would be needed for a comprehensive assessment.

How does the $658 million FY2021 spending compare to previous years for this contract or similar VA pharmaceutical prime vendor contracts?

To accurately compare the $658 million FY2021 spending, historical data for this specific contract or similar VA pharmaceutical prime vendor contracts would be required. The VA's pharmaceutical spending can fluctuate based on factors such as changes in veteran population, healthcare utilization patterns, drug formulary adjustments, and the introduction of new, more expensive medications. Generally, the demand for pharmaceuticals has been on an upward trend due to an aging veteran population and advancements in medical treatments. Therefore, it would not be surprising if FY2021 spending represents a continuation or increase compared to prior years. A detailed analysis would involve examining annual spending reports for the PPV program over the last 5-10 years to identify trends and understand the drivers of any significant variations.

What are the primary risks associated with relying on a single prime vendor like McKesson for such a large volume of pharmaceuticals?

Relying on a single prime vendor for a substantial volume of pharmaceuticals presents several key risks. Firstly, there is a significant supply chain disruption risk; if McKesson faces operational issues (e.g., natural disasters affecting distribution centers, labor strikes, or internal system failures), it could lead to widespread drug shortages across VA facilities. Secondly, there's a potential for reduced price competition over time, as the incumbent vendor may have less incentive to offer aggressive pricing once established. Thirdly, dependence on one vendor can limit the VA's flexibility to quickly adopt new distribution models or integrate with emerging technologies. Finally, quality control and compliance monitoring become critical, as any lapse by the prime vendor could have direct implications for patient safety and medication integrity.

What is the typical profit margin or cost structure for pharmaceutical prime vendors serving the federal government?

The typical profit margin for pharmaceutical prime vendors serving the federal government, like McKesson, is generally considered to be relatively slim, often in the low single digits (e.g., 1-3% net profit). This is because these contracts are typically awarded under firm-fixed-price or similar pricing structures that limit upside potential for the contractor. The government negotiates prices based on market data, volume discounts, and competitive bidding. The prime vendor's cost structure includes the acquisition cost of pharmaceuticals, significant operational expenses for warehousing, logistics, inventory management, IT systems, regulatory compliance, and personnel. While the profit margin per unit may be small, the sheer volume of sales through large contracts like the VA's PPV program allows these companies to achieve substantial overall revenue and profitability.

How does the VA ensure the quality and integrity of pharmaceuticals distributed through its prime vendor contracts?

The VA employs multiple mechanisms to ensure the quality and integrity of pharmaceuticals distributed through its prime vendor contracts. Firstly, contractors must adhere to strict regulatory requirements set forth by the Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA), including Good Distribution Practices (GDP). Secondly, the contract itself will contain specific clauses regarding quality control, product handling, storage conditions (e.g., temperature control), and recall procedures. The VA conducts regular oversight, including site visits to distribution centers and audits of inventory management and record-keeping. Furthermore, the VA's own pharmacy services and clinical staff monitor medication quality and patient outcomes. Any deviations or non-compliance can result in contractual penalties or termination.

What is the strategic importance of the Pharmaceutical Prime Vendor (PPV) program to the VA's overall healthcare mission?

The Pharmaceutical Prime Vendor (PPV) program is strategically vital to the VA's healthcare mission because it ensures a reliable, efficient, and cost-effective supply of essential medications to veterans across the country. By consolidating pharmaceutical procurement and distribution through a prime vendor, the VA can achieve economies of scale, reduce administrative overhead, and maintain adequate inventory levels to meet the diverse and often urgent needs of its patient population. This program allows the VA to focus its resources on direct patient care rather than managing complex pharmaceutical logistics. The PPV program is a critical component of the VA's supply chain resilience, ensuring that healthcare providers have the necessary drugs to treat veterans, thereby supporting the VA's commitment to providing high-quality, comprehensive healthcare services.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 6555 STATE HIGHWAY 161, IRVING, TX, 75039

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $658,334,795

Exercised Options: $658,334,795

Current Obligation: $658,334,795

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL ITEM

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36W79720D0001

IDV Type: IDC

Timeline